You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Breast cancer

Gemcitabine for the treatment of metastatic breast cancer

  • Technology appraisal guidance
  • Reference number: TA116
  • Published:  24 January 2007
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
Download guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 The technology
  • 3 The manufacturer's submission
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Appraisal Committee members and NICE project team
  • 7 Sources of evidence considered by the Committee
  • Update information

1 Recommendations

1.1

Gemcitabine in combination with paclitaxel, within its licensed indication, is recommended as an option for the treatment of metastatic breast cancer only when docetaxel monotherapy or docetaxel plus capecitabine are also considered appropriate.


Next page 2 The technology Previous page Overview
Back to top